Drug Trial Radar · NCT07563738
A 2-part Phase 1/2 Open-label Trial on ODM-212
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
229
Planned (sponsor's estimate)
Start
Mar 27, 2026
Primary completion
Sep 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Orion Corporation, Orion PharmaIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
Conditions
- Mesothelioma
- Pancreatic Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
ODM-212Drug
ODM-212 40mg tablet
Ipilimumab and nivolumabDrug
Ipilimumab: 1 mg/kg administered intravenously over 30 minutes every 6 weeks. Nivolumab: 360 mg administered intravenously over 30 minutes every 3 weeks.
Gemcitabine and nab-paclitaxelDrug
Nab-paclitaxel 125 mg/m2 administered intravenously over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. Gemcitabine 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of nab-paclitaxel administration on days 1, 8 and 15 of each 28-day cycle
sotorasibDrug
Sotorasib total daily dose of 960 mg taken orally q.d. every day of the 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities and Adverse EventsTime frame: Through study completion, on average of 2 years
Locations
23 sites in 7 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
UC Irvine Health
Orange, California · Recruiting
START Dallas-Fort Worth
Fort Worth, Texas · Recruiting
NEXT Oncology
Irving, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Aalborg Universitets hospital
Aalborg, Denmark · Recruiting
Rigshospitalet University
Copenhagen, Denmark · Recruiting
Helsinki University Hospital
Helsinki, Finland · Recruiting
Turku University Hospital
Turku, Finland · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Marseille University Hospital Timone
Marseille, France · Recruiting
CHU de Poitiers
Poitiers, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
HM Nou Delfos
Barcelona, Spain · Recruiting
ICO Hospitale
Barcelona, Spain · Recruiting
Vall D'Hebron University Hospital
Barcelona, Spain · Recruiting
HM Sanchinarro
Madrid, Spain · Recruiting
Hospital 12 de Octubre
Madrid, Spain · Recruiting
START Madrid FJD
Madrid, Spain · Recruiting
Ospedale Regionale Bellinzona
Bellinzona, Switzerland · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Recruiting
Royal Marsden Hospital
London, United Kingdom · Recruiting
University Hospital Southampton
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.